Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic hematopoietic cell transplantation for patients with hematologic disorders who are ineligible or inappropriate for treatment with a more intensive therapeutic regimen.

Next Previous
X
Search
Trial Profile

Allogeneic hematopoietic cell transplantation for patients with hematologic disorders who are ineligible or inappropriate for treatment with a more intensive therapeutic regimen.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab; Antithymocyte globulin; Busulfan; Fludarabine; Methotrexate; Sargramostim; Tacrolimus
  • Indications Graft-versus-host disease; Haematological malignancies
  • Focus Therapeutic Use

    • Most Recent Events

    • 30 May 2017 Biomarkers information updated
    • 15 Feb 2013 Planned end date changed from 1 Dec 2012 to 1 Jul 2014 as reported by ClinicalTrials.gov.
    • 21 Feb 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top